Articles tagged with: Blood Cancers

CRUK Gibraltar Committee visit the BCI

Posted in General News, Engagement Published by Bethan Warman 18 July 2018

CRUK Gibraltar Committee visit the BCI

We were recently visited by two members of the CRUK Gibraltar Committee, Giovi and Deborah, who came to the BCI for a laboratory tour with Dr Ana Rio-Machin, a postdoctoral researcher in the Centre for Haemato-Oncology. Ana’s research focuses on leukaemia, a type of blood cancer in which patients present an abnormal growth of white blood cells.

Following an introduction to the work that is conducted here to help better understand and treat leukaemia, provided by Ana’s supervisor, Prof Jude Fitzgibbon, Giovi and Deborah visited the laboratories to see where this research takes place.

Follicular lymphoma marked by spatial tumour heterogeneity

Posted in General News, Publications Published by Bethan Warman 23 March 2018

A challenge for targeted therapy

Follicular lymphoma marked by spatial tumour heterogeneity

A research team at the BCI, Queen Mary University of London, led by Dr Jessica Okosun, Centre for Haemato-Oncology, has found that tumours at different sites within the same patient with follicular lymphoma can be genetically diverse. This suggests that a sole biopsy is incapable of capturing all the genetic events in any given individual and presents a significant challenge when providing targeted therapies to treat this disease.

Follicular lymphoma is an incurable blood cancer that is characterised by the production of abnormal B lymphocytes (a type of white blood cell involved in fighting infection) that accumulate primarily in the lymph nodes and bone marrow. Approximately 2,300 cases of follicular lymphoma are diagnosed in the UK each year.

Some leukaemia patients may be missing out on new treatments

Posted in General News, Publications Published by Bethan Warman 11 January 2018

Some leukaemia patients may be missing out on new treatments

Patients with an aggressive form of leukaemia, currently ineligible for any type of targeted therapy, may in fact benefit from new drugs, according to new research by Barts Cancer Institute at Queen Mary University of London.

One such drug, named midostaurin, was recently approved by the US Food and Drug Administration to treat this type of leukaemia, but only patients who show mutations on a gene named FLT3 are eligible for treatment.

BCI at the 59th ASH Annual Meeting

Posted in General News, Conferences, BCI on the Road Published by Reza Roozitalab 08 December 2017

"The most prestigious event in the haematology calendar"

BCI at the 59th ASH Annual Meeting

Research teams from our Centre for Haemato-Oncology have once again joined the world’s most influential figures in haematology to present their cutting-edge findings at the 59th ASH Annual Meeting & Exposition.

A New Target Linked with Several Aggressive Forms of Blood Tumour

Posted in General News, Publications Published by Reza Roozitalab 23 October 2017

Lamin B1 - a potential target for follicular lymphoma and Chronic lymphocytic leukaemia

A New Target Linked with Several Aggressive Forms of Blood Tumour

Manipulating levels of Lamin B1 may one day prove an effective treatment option for patients with lymphomas and chronic lymphocytic leukaemia...

New Group Leaders at BCI

Posted in General News Published by Reza Roozitalab 16 October 2017

New and familiar faces at Barts Cancer Institute

New Group Leaders at BCI

Congratulations to academic staff members Dr Jessica Okosun & Kevin Rouault-Pierre from our Centre for Haematology Oncology and Dr Oliver Pearce from the Centre for Cancer & Inflammation! 

Find out more about the research that our new group leaders will carry out...

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.